Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lifestance Health Group (LFST – Research Report) and Beam Therapeutics (BEAM – Research Report).
Lifestance Health Group (LFST)
Goldman Sachs analyst Jamie Perse maintained a Hold rating on Lifestance Health Group on August 9. The company’s shares closed last Friday at $8.16.
According to TipRanks.com, Perse is a 3-star analyst with an average return of
Currently, the analyst consensus on Lifestance Health Group is a Hold with an average price target of $9.50, a 15.2% upside from current levels. In a report issued on August 10, J.P. Morgan also maintained a Hold rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Beam Therapeutics (BEAM)
In a report issued on August 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. The company’s shares closed last Friday at $25.55, close to its 52-week low of $25.01.
According to TipRanks.com, Corwin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Beam Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $51.00, representing a 103.2% upside. In a report issued on August 8, Citi also maintained a Buy rating on the stock with a $56.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LFST:
